LRG1, His, Cynomolgus
LRG1, His, Cynomolgus

Immobilized LRG1, His, Cynomolgus, His Tag at 5 μg /ml(100 μl /well) on the plate. Dose response curve for Anti-LRG1 Antibody, hFc Tag with the EC50 of 90.1ng/ml determined by ELISA.

LRG1, His, Cynomolgus

The purity of LRG1, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

LRG1, His, Cynomolgus

LRG1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LRG1, His, Cynomolgus

Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN.
Z04861
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
LRG1 (Val72-Gln383)
Accession # A0A2K5VVA4		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 35.69 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LRG1, His, Cynomolgus
    • LRG1, His, Cynomolgus

    Immobilized LRG1, His, Cynomolgus, His Tag at 5 μg /ml(100 μl /well) on the plate. Dose response curve for Anti-LRG1 Antibody, hFc Tag with the EC50 of 90.1ng/ml determined by ELISA.

  • LRG1, His, Cynomolgus
    • LRG1, His, Cynomolgus

    The purity of LRG1, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • LRG1, His, Cynomolgus
    • LRG1, His, Cynomolgus

    LRG1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN.
Synonyms Leucine-rich alpha-2-glycoprotein; LRG;LRG1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.